ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 1745

Exploring the Risk of Ocular Adverse Events Associated with Janus Kinase Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)

Maria Shamsi1, Aisha Mansur2, Achsah Venite Karra3 and Rita-Nour Antoine Awad4

Affiliations: 1SOVAH Health Danville Internal Medicine Residency Program, Danville, VA, 2University of Tripoli, Tripoli, Libya, 3Jawaharlal Institute of postgraduate Medical Education and Research- JIPMER Puducherry, Hyderabad, India, 4University of Balamand, Koura, Lebanon

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: autoimmune diseases, Biologicals, Data Management, Eye Disorders, Pharmacoepidemiology

Session Information

Date: Monday, November 9, 2026

Title: (1735-1769) Epidemiology & Public Health Poster B

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Janus kinase (JAK) inhibitors are increasingly used for rheumatoid arthritis and other immune-mediated diseases. While cardiovascular, infectious, thromboembolic, and malignant adverse events have been extensively studied, less is known about their ocular safety profile. Ocular adverse events have been reported in clinical studies and post-marketing settings, but their reporting patterns remain poorly characterized. To further characterize the ocular safety profile of JAK inhibitors, we conducted a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS).

Methods: A retrospective pharmacovigilance analysis was conducted using FAERS reports submitted from January 2015 through December 2025. Ocular adverse events were identified using MedDRA Preferred Terms, including blurred vision, visual impairment, reduced visual acuity, conjunctivitis, keratitis, uveitis, retinal disorder, retinal detachment, retinal hemorrhage, optic neuritis, and macular edema. Reports associated with tofacitinib, baricitinib, and abrocitinib were evaluated. Disproportionality analysis was performed using reporting odds ratios (RORs), proportional reporting ratios (PRRs), chi-square statistics, and 95% confidence intervals.

Results: A total of 22,828,657 adverse event reports were identified in the FAERS database between 2015 and 2025. Among JAK inhibitors, 121 ocular adverse event reports were associated with tofacitinib, 72 with baricitinib, and 51 with abrocitinib.

Visual impairment was the most frequently reported ocular adverse event among tofacitinib users (86 reports), whereas blurred vision was the most commonly reported event among baricitinib (13 reports) and abrocitinib users (17 reports). Uveitis was reported in 26 tofacitinib-associated cases and 11 baricitinib-associated cases.

Tofacitinib demonstrated disproportionate reporting of ocular adverse events overall (ROR 3.13, 95% CI 2.61-3.75). The strongest individual safety signals were observed for uveitis (ROR 15.70, 95% CI 10.67-23.09), keratitis (ROR 6.21, 95% CI 1.55-24.87), visual impairment (ROR 5.55, 95% CI 4.48-6.87), and conjunctivitis (ROR 5.40, 95% CI 3.06-9.52). Baricitinib demonstrated significant signals for keratitis (ROR 4.19, 95% CI 1.35-13.02), uveitis (ROR 2.97, 95% CI 1.64-5.36), and conjunctivitis (ROR 2.22, 95% CI 1.23-4.02). Among abrocitinib users, significant disproportionality signals were identified for keratitis (ROR 7.03, 95% CI 1.76-28.13), conjunctivitis (ROR 4.58, 95% CI 2.38-8.81), and retinal detachment (ROR 3.63, 95% CI 1.17-11.25).

Conclusion: JAK inhibitors were associated with a spectrum of reported ocular adverse events in the FAERS database. Tofacitinib demonstrated the strongest and broadest ocular safety signals, particularly for uveitis, keratitis, visual impairment, and conjunctivitis. Baricitinib and abrocitinib were associated with fewer but notable ocular signals. These findings highlight the importance of clinician awareness of visual symptoms in patients receiving JAK inhibitors and support further pharmacoepidemiologic and prospective studies to clarify causality and characterize drug-specific ocular safety profiles.

Supporting image 1Table 1. Frequency and disproportionality analysis of ocular adverse events associated with Janus kinase (JAK) inhibitors

Supporting image 2Figure 1: Frequency of Reported Odds Ratio (ROR) of Janus kinase (JAK) inhibitors

Supporting image 3Figure 2: Forest Plot of Reporting Odds Ratios for Ocular Adverse Events Associated with Tofacitinib, Baricitinib, and Abrocitinib


Disclosures: M. Shamsi: None; A. Mansur: None; A. Venite Karra: None; R. Antoine Awad: None.

To cite this abstract in AMA style:

Shamsi M, Mansur A, Venite Karra A, Antoine Awad R. Exploring the Risk of Ocular Adverse Events Associated with Janus Kinase Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS) [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/exploring-the-risk-of-ocular-adverse-events-associated-with-janus-kinase-inhibitors-analysis-of-the-fda-adverse-event-reporting-system-faers/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-the-risk-of-ocular-adverse-events-associated-with-janus-kinase-inhibitors-analysis-of-the-fda-adverse-event-reporting-system-faers/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology